Veteran biotech executive Jeremy Levin discusses how the industry faces a critical juncture with $2.6 billion average drug development costs and declining venture funding. Companies must fundamentally rethink traditional business models to navigate regulatory complexity and innovation demands. โ Photo by Jess Loiterton on Pexels (Pexels License)
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.
